Novel drug targets based on metallobiology of Alzheimer's disease

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 11, 2010, Pages 1177-1197

  Bandyopadhyay, Sanghamitra ^a   Huang, Xudong ^b,d   Lahiri, Debomoy K ^c   Rogers, Jack T ^d  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

A ; APP; Iron responsive element; Metal chelators; Screening

Indexed keywords

1 (BENZIMIDAZOLE 2 YLMETHYL) 1,4,7 TRIAZACYCLONONANE; 1,4 BIS(BENZIMIDAZOLE 2 YLMETHYL) 1,4,7 TRIAZACYCLONONE); 2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; 5 (4 PROPARGYLPIPERAZIN 1 YLMETHYL) 8 HYDROXYQUINOLINE; 5 (N METHYL N PROPARGYLAMINOMETHYL) 8 HYDROXYQUINOLINE; 6 HYDROXYMELATONIN; ALPHA TOCOPHEROL; ALUMINUM; AMYLOID BETA PROTEIN; ASCORBIC ACID; CLIOQUINOL; COPPER; CURCUMIN; DEFEROXAMINE; DP 109; EPIGALLOCATECHIN GALLATE; GOSSYPINE; HLA 20; IRON; KAEMPFEROL; M 30A; NOOTROPIC AGENT; PBT 2; PENICILLAMINE; QUINOLINE DERIVATIVE; RASAGILINE; RESVERATROL; SELEGILINE; TACRINE; UNCLASSIFIED DRUG; VK 28; ZINC;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN PROTECTION; CHELATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; HUMAN; METAL BINDING; MOLECULARLY TARGETED THERAPY; NERVE CONDUCTION; NEUROTOXICITY; NONHUMAN; PROTEIN INTERACTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SUBACUTE MYELOOPTIC NEUROPATHY; TARGET CELL;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIOXIDANTS; CHELATING AGENTS; CHELATION THERAPY; DRUG DESIGN; HUMANS; METALS; PLAQUE, AMYLOID; SYNAPTIC TRANSMISSION;

EID: 77958046282     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.525352     Document Type: Review

References (228)

1. Grill JD, Cummings JL. Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev Neurother 2010;10:711-728
2. De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 2010;90:465-494
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356
4. Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 2010;19(R1):R4-11
5. Bush AI, Tanzi RE. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 2008;5:421-432
6. Lovell MA, Robertson JD, Teesdale WJ, et al. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998;158:47-52
7. Liu G, Huang W, Moir RD, et al. Metal exposure and Alzheimer's pathogenesis. J Struct Biol 2006;155:45-51
8. Rogers JT, Bush AI, Cho HH, et al. Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease. Biochem Soc Trans 2008;36:1282-1287
9. Leskovjan AC, Lanzirotti A, Miller LM. Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease. Neuroimage 2009;47:1215-1220
10. Stoltenberg M, Bruhn M, Sondergaard C, et al. Immersion autometallographic tracing of zinc ions in Alzheimer beta-amyloid plaques. Histochem Cell Biol 2005;123:605-611
11. Danscher G, Jensen KB, Frederickson CJ, et al. Increased amount of zinc in the hippocampus and amygdala of Alzheimer's diseased brains: a proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. J Neurosci Methods 1997;76:53-59
12. Miller LM, Wang Q, Telivala TP, et al. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. J Struct Biol 2006;155:30-37
13. McCrea RP, Harder SL, Martin M, et al. A comparison of rapid-scanning X-ray fluorescence mapping and magnetic resonance imaging to localize brain iron distribution. Eur J Radiol 2008;68:S109-13
14. Bartzokis G, Sultzer D, Mintz J, et al. In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI. Biol Psychiatry 1994;35:480-487
15. Yamamoto A, Shin RW, Hasegawa K, et al. Iron (III) induces aggregation of hyperphosphorylated t and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. J Neurochem 2002;82:1137-1147
16. Kitazawa M, Cheng D, Laferla FM. Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD. J Neurochem 2009;108:1550-1560
17. Lahiri DK, Ge YW, Maloney B. Characterization of the APP proximal promoter and 5¢-untranslated regions: identification of cell type-specific domains and implications in APP gene expression and Alzheimer's disease. FASEB J 2005;19:653-655
18. Maloney B, Ge YW, Greig N, Lahiri DK. Presence of a "CAGA box" in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: implications in Alzheimer's disease. FASEB J 2004;18:1288-1290
19. Bandyopadhyay S, Huang X, Cho H, et al. Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5¢untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator. J Neural Transm Suppl 2006;71:237-247
20. Silvestri L, Camaschella C. A potential pathogenetic role of iron in Alzheimer's disease. J Cell Mol Med 2008;12:1548-1550
21. Gourley BL, Parker SB, Jones BJ, et al. Cytosolic aconitase and ferritin are regulated by iron in Caenorhabditis elegans. J Biol Chem 2003;278:3227-3234
22. Smith MA, Wehr K, Harris PL, et al. Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res 1998;788:232-236
23. Rogers JT, Leiter LM, McPhee J, et al. Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5¢-untranslated region sequences. J Biol Chem 1999;274:6421-6431
24. Rogers JT, Randall JD, Cahill CM, et al. An iron-responsive element type II in the 5¢-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 2002;277:45518-45528
25. Athan ES, Lee JH, Arriaga A, et al. Polymorphisms in the promoter of the human APP gene: functional evaluation and allele frequencies in Alzheimer disease. Arch Neurol 2002;59:1793-1799
26. Jefferies WA, Food MR, Gabathuler R, et al. Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res 1996;712:122-126
27. Connor JR, Menzies SL, St Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 1992;31:75-83
28. Grundke-Iqbal I, Fleming J, Tung YC, et al. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol 1990;81:105-110
29. Sayre LM, Perry G, Harris PL, et al. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 2000;74:270-279
30. Pinero DJ, Hu J, Connor JR. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. Cell Mol Biol (Noisy-le-grand) 2000;46:761-776
31. Robson KJ, Lehmann DJ, Wimhurst VL, et al. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J Med Genet 2004;41:261-265
32. Lehmann DJ, Worwood M, Ellis R, et al. Iron genes, iron load and risk of Alzheimer's disease. J Med Genet 2006;43(10):e52
33. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997;94:9866-9868
34. Smith MA, Hirai K, Hsiao K, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998;70:2212-2215
35. Jiang D, Li X, Williams R, et al. Ternary complexes of iron, amyloid-beta, and nitrilotriacetic acid: binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease. Biochemistry 2009;48:7939-7947
36. Khan A, Dobson JP, Exley C. Redox cycling of iron by Abeta42. Free Radic Biol Med 2006;40:557-569
37. Exley C. Aluminium and iron, but neither copper nor zinc, are key to the precipitation of beta-sheets of Abeta42. in senile plaque cores in Alzheimer's disease. J Alzheimers Dis 2006;10:173-177
38. Collingwood JF, Chong RK, Kasama T, et al. Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer's plaque core material. J Alzheimers Dis 2008;14:235-245
39. Thompson K, Menzies S, Muckenthaler M, et al. Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J Neurosci Res 2003;71:46-63
40. Atamna H, Boyle K. Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. Proc Natl Acad Sci USA 2006;103:3381-3386
41. Dwyer BE, Smith MA, Richardson SL, et al. Down-regulation of aminolevulinate synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer's disease. Neurosci Lett 2009;460:180-184
42. Magaki S, Raghavan R, Mueller C, et al. Iron, copper, and iron regulatory protein 2 in Alzheimer's disease and related dementias. Neurosci Lett 2007;418:72-76
43. Atamna H, Frey WH II. A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism. Proc Natl Acad Sci USA 2004;101:11153-11158
44. Schipper HM, Gupta A, Szarek WA. Suppression of Glial HO-1 activitiy as a potential neurotherapeutic intervention in AD. Curr Alzheimer Res 2009 published online Oct 1 2009. doi: 10.2174/ 156720509789207985
45. Perry G, Taddeo MA, Petersen RB, et al. Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals 2003;16:77-81
46. Schubert D, Chevion M. The role of iron in beta amyloid toxicity. Biochem Biophys Res Commun 1995;216:702-707
47. Rogers JT, Lahiri DK. Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets 2004;5:535-551
48. Velez-Pardo C, Ospina GG, Jimenez del Rio M. Abeta[25-35] peptide and iron promote apoptosis in lymphocytes by an oxidative stress mechanism: involvement of H2O2, caspase-3, NF-kappaB, p53 and c-Jun. Neurotoxicology 2002;23:351-365
49. Ghribi O, Golovko MY, Larsen B, et al. Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J Neurochem 2006;99:438-449
50. Quintana C, Bellefqih S, Laval JY, et al. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J Struct Biol 2006;153:42-54
51. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 2004;25:5-18; author reply 49-62
52. Rottkamp CA, Raina AK, Zhu X, et al. Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 2001;30:447-450
53. Suh SW, Jensen KB, Jensen MS, et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res 2000;852:274-278
54. Frederickson CJ, Cuajungco MP. Is zinc the link between compromises of brain perfusion (excitotoxicity) and Alzheimer's disease? J Alzheimers Dis 2005;8:155-60; discussion 209-215
55. Uchida Y, Takio K, Titani K, et al. The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron 1991;7:337-347
56. Backstrom JR, Miller CA, Tokes ZA. Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus. J Neurochem 1992;58:983-992
57. Stewart GR, Frederickson CJ, Howell GA, Gage FH. Cholinergic denervation-induced increase of chelatable zinc in mossy-fiber region of the hippocampal formation. Brain Res 1984;290:43-51
58. Frederickson CJ, Koh JY, Bush AI. The neurobiology of zinc in health and disease. Nat Rev Neurosci 2005;6:449-462
59. Zhang LH, Wang X, Zheng ZH, et al. Altered expression and distribution of zinc transporters in APP/PS1 transgenic mouse brain. Neurobiol Aging 2010;31:74-87
60. Zhang LH, Wang X, Stoltenberg M, et al. Abundant expression of zinc transporters in the amyloid plaques of Alzheimer's disease brain. Brain Res Bull 2008;77:55-60
61. Bush AI, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994;265:1464-1467
62. Mocchegiani E, Costarelli L, Giacconi R, et al. Zinc homeostasis in aging: two elusive faces of the same "metal". Rejuvenation Res 2006;9:351-354
63. Kambe T, Yamaguchi-Iwai Y, Sasaki R, Nagao M. Overview of mammalian zinc transporters. Cell Mol Life Sci 2004;61:49-68
64. Friedlich AL, Lee JY, van Groen T, et al. Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer's disease. J Neurosci 2004;24:3453-3459
65. Lee JY, Cole TB, Palmiter RD, et al. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci USA 2002;99:7705-7710
66. Bush AI, Multhaup G, Moir RD, et al. A novel zinc(II) binding site modulates the function of the betaA4 amyloid protein precursor of Alzheimer's disease. J Biol Chem 1993;268:16109-16112
67. Bush AI, Pettingell WH Jr, de Paradis M, et al. The amyloid beta-protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin-binding superfamily. J Biol Chem 1994;269:26618-26621
68. Multhaup G, Mechler H, Masters CL. Characterization of the high affinity heparin binding site of the Alzheimer's disease betaA4 amyloid precursor protein (APP) and its enhancement by zinc(II). J Mol Recognit 1995;8:247-257
69. Narindrasorasak S, Lowery DE, Altman RA, et al. Characterization of high affinity binding between laminin and Alzheimer's disease amyloid precursor proteins. Lab Invest 1992;67:643-652
70. Huang X, Cuajungco MP, Atwood CS, et al. Alzheimer's disease, beta-amyloid protein and zinc. J Nutr 2000;130(5S Suppl):1488S-1492S
71. Roberts SB, Ripellino JA, Ingalls KM, et al. Non-amyloidogenic cleavage of the beta-amyloid precursor protein by an integral membrane metalloendopeptidase. J Biol Chem 1994;269:3111-3116
72. Park IH, Jung MW, Mori H, Mook-Jung I. Zinc enhances synthesis of presenilin 1 in mouse primary cortical culture. Biochem Biophys Res Commun 2001;285:680-688
73. Cuajungco MP, Lees GJ. Zinc metabolism in the brain: relevance to human neurodegenerative disorders. Neurobiol Dis 1997;4:137-169
74. Vener AV, Aksenova MV, Burbaeva G. Drastic reduction of the zinc- and magnesium-stimulated protein tyrosine kinase activities in Alzheimer's disease hippocampus. FEBS Lett 1993;328:6-8
75. Bush AI, Pettingell WH Jr, Paradis MD, Tanzi RE. Modulation of Abeta adhesiveness and secretase site cleavage by zinc. J Biol Chem 1994;269:12152-12158
76. Noy D, Solomonov I, Sinkevich O, et al. Zinc-amyloid beta interactions on a millisecond time-scale stabilize non-fibrillar Alzheimer-related species. J Am Chem Soc 2008;130:1376-1383
77. Kozin SA, Zirah S, Rebuffat S, et al. Zinc binding to Alzheimer's Abeta(1-16) peptide results in stable soluble complex. Biochem Biophys Res Commun 2001;285:959-964
78. Smith DP, Smith DG, Curtain CC, et al. Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. J Biol Chem 2006;281:15145-15154
79. Danielsson J, Pierattelli R, Banci L, Graslund A. High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid beta-peptide. FEBS J 2007;274:46-59
80. Faller P, Hureau C. Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-beta peptide. Dalton Trans 2009;(7):1080-1094
81. Gaggelli E, Janicka-Klos A, Jankowska E, et al. NMR studies of the Zn2+ interactions with rat and human beta-amyloid (1-28) peptides in water-micelle environment. J Phys Chem B 2008;112:100-109
82. Zirah S, Kozin SA, Mazur AK, et al. Structural changes of region 1-16 of the Alzheimer disease amyloid beta-peptide upon zinc binding and in vitro aging. J Biol Chem 2006;281:2151-2161
83. Talmard C, Bouzan A, Faller P. Zinc binding to amyloid-beta: isothermal titration calorimetry and Zn competition experiments with Zn sensors. Biochemistry 2007;46:13658-13666
84. Tsvetkov PO, Popov IA, Nikolaev EN, et al. Isomerization of the Asp7 residue results in zinc-induced oligomerization of Alzheimer's disease amyloid beta(1-16) peptide. Chembiochem 2008;9:1564-1567
85. Tougu V, Karafin A, Zovo K, et al. Zn(II)- and Cu(II)-induced nonfibrillar aggregates of amyloid-beta (1-42) peptide are transformed to amyloid fibrils, both spontaneously and under the influence of metal chelators. J Neurochem 2009;110:1784-1795
86. Talmard C, Leuma Yona R, Faller P. Mechanism of zinc(II)-promoted amyloid formation: zinc(II) binding facilitates the transition from the partially alpha-helical conformer to aggregates of amyloid beta protein(1-28). J Biol Inorg Chem 2009;14:449-455
87. Yu WH, Fraser PE. S100beta interaction with tau is promoted by zinc and inhibited by hyperphosphorylation in Alzheimer's disease. J Neurosci 2001;21:2240-2246
88. Squitti R, Quattrocchi CC, Salustri C, Rossini PM. Ceruloplasmin fragmentation is implicated in 'free' copper deregulation of Alzheimer's disease. Prion 2008;2:23-27
89. Maynard CJ, Bush AI, Masters CL, et al. Metals and amyloid-beta in Alzheimer's disease. Int J Exp Pathol 2005;86:147-159
90. Bica L, Crouch PJ, Cappai R, White AR. Metallo-complex activation of neuroprotective signalling pathways as a therapeutic treatment for Alzheimer's disease. Mol Biosyst 2009;5:134-142
91. Hureau C, Faller P. Abeta-mediated ROS production by Cu ions: structural insights, mechanisms and relevance to Alzheimer's disease. Biochimie 2009;91:1212-1217
92. Hung YH, Bush AI, Cherny RA. Copper in the brain and Alzheimer's disease. J Biol Inorg Chem 2010;15:61-76
93. Moreira PI, Santos MS, Oliveira CR, et al. Alzheimer disease and the role of free radicals in the pathogenesis of the disease. CNS Neurol Disord Drug Targets 2008;7:3-10
94. Squitti R, Bressi F, Pasqualetti P, et al. Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease. Neurology 2009;72:50-55
95. Butterfield DA, Reed T, Newman SF, Sultana R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 2007;43:658-677
96. Opazo C, Huang X, Cherny RA, et al. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H2O2. J Biol Chem 2002;277:40302-40308
97. Atwood CS, Perry G, Zeng H, et al. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 2004;43:560-568
98. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994;77:817-827
99. Barnham KJ, Haeffner F, Ciccotosto GD, et al. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J 2004;18:1427-1429
100. Atwood CS, Moir RD, Huang X, et al. Dramatic aggregation of Alzheimer Abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998;273:12817-12826
101. Sparks DL, Petanceska S, Sabbagh M, et al. Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Curr Alzheimer Res 2005;2:527-539
102. Hayashi T, Shishido N, Nakayama K, et al. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide. Free Radic Biol Med 2007;43:1552-1559
103. Hung YH, Robb EL, Volitakis I, et al. Paradoxical condensation of copper with elevated beta-amyloid in lipid rafts under cellular copper deficiency conditions: implications for Alzheimer disease. J Biol Chem 2009;284:21899-21907
104. Nadal RC, Rigby SE, Viles JH. Amyloid beta-Cu2+ complexes in both monomeric and fibrillar forms do not generate H2O2 catalytically but quench hydroxyl radicals. Biochemistry 2008;47:11653-11664
105. Hesse L, Beher D, Masters CL, Multhaup G. The betaA4 amyloid precursor protein binding to copper. FEBS Lett 1994;349:109-116
106. Multhaup G, Schlicksupp A, Hesse L, et al. The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). Science 1996;271:1406-1409 (Pubitemid 26089474)
107. Kong GK, Miles LA, Crespi GA, et al. Copper binding to the Alzheimer's disease amyloid precursor protein. Eur Biophys J 2008;37:269-279
108. Kong GK, Adams JJ, Harris HH, et al. Structural studies of the Alzheimer's amyloid precursor protein copper-binding domain reveal how it binds copper ions. J Mol Biol 2007;367:148-161
109. Dingwall C. A copper-binding site in the cytoplasmic domain of BACE1 identifies a possible link to metal homoeostasis and oxidative stress in Alzheimer's disease. Biochem Soc Trans 2007;35:571-573
110. Bellingham SA, Lahiri DK, Maloney B, et al. Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. J Biol Chem 2004;279:20378-20386
111. White AR, Reyes R, Mercer JF, et al. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res 1999;842:439-444
112. Karr JW, Akintoye H, Kaupp LJ, Szalai VA. N-Terminal deletions modify the Cu2+ binding site in amyloid-beta. Biochemistry 2005;44:5478-5487
113. Rozga M, Bal W. The Cu(II)/Abeta/ human serum albumin model of control mechanism for copper-related amyloid neurotoxicity. Chem Res Toxicol 2010;23:298-308
114. Rauk A. The chemistry of Alzheimer's disease. Chem Soc Rev 2009;38:2698-2715
115. Metodiewa D. Molecular mechanisms of cellular injury produced by neurotoxic amino acids that generate reactive oxygen species. Amino Acids 1998;14:181-187
116. Shin BK, Saxena S. Direct evidence that all three histidine residues coordinate to Cu(II) in amyloid-beta1-16. Biochemistry 2008;47:9117-9123
117. Drew SC, Noble CJ, Masters CL, et al. Pleomorphic copper coordination by Alzheimer's disease amyloid-beta peptide. J Am Chem Soc 2009;131:1195-1207
118. Drew SC, Masters CL, Barnham KJ. Alanine-2 carbonyl is an oxygen ligand in Cu2+ coordination of Alzheimer's disease amyloid-beta peptide - relevance to N-terminally truncated forms. J Am Chem Soc 2009;131:8760-8761
119. Dorlet P, Gambarelli S, Faller P, Hureau C. Pulse EPR spectroscopy reveals the coordination sphere of copper(II) ions in the 1-16 amyloid-beta peptide: a key role of the first two N-terminus residues. Angew Chem Int Ed Engl 2009;48:9273-9276
120. Shearer J, Szalai VA. The amyloid-beta peptide of Alzheimer's disease binds CuI in a linear bis-his coordination environment: insight into a possible neuroprotective mechanism for the amyloid-beta peptide. J Am Chem Soc 2008;13:17826-17835
121. Hureau C, Balland V, Coppel Y, et al. Importance of dynamical processes in the coordination chemistry and redox conversion of copper amyloid-beta complexes. J Biol Inorg Chem 2009;14:995-1000
122. Himes RA, Park GY, Siluvai GS, et al. Structural studies of copper(I) complexes of amyloid-beta peptide fragments: formation of two-coordinate bis (histidine) complexes. Angew Chem Int Ed Engl 2008;47:9084-90877
123. da Silva GF, Tay WM, Ming LJ. Catechol oxidase-like oxidation chemistry of the 1-20 and 1-16 fragments of Alzheimer's disease-related beta-amyloid peptide: their structure-activity correlation and the fate of hydrogen peroxide. J Biol Chem 2005;280:16601-16609
124. Syme CD, Nadal RC, Rigby SE, Viles JH. Copper binding to the amyloid-beta (Abeta) peptide associated with Alzheimer's disease: folding, coordination geometry, pH dependence, stoichiometry, and affinity of Abeta-(1-28): insights from a range of complementary spectroscopic techniques. J Biol Chem 2004;279:18169-18177
125. Tickler AK, Smith DG, Ciccotosto GD, et al. Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J Biol Chem 2005;280:13355-13363
126. Karr JW, Kaupp LJ, Szalai VA. Amyloid-beta binds Cu2+ in a mononuclear metal ion binding site. J Am Chem Soc 2004;126:13534-13538
127. Nakamura M, Shishido N, Nunomura A, et al. Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. Biochemistry 2007;46:12737-12743
128. Curtain CC, Ali F, Volitakis I, et al. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 2001;276:20466-20473
129. Tougu V, Karafin A, Palumaa P. Binding of zinc(II) and copper(II) to the full-length Alzheimer's amyloid-beta peptide. J Neurochem 2008;104:1249-1259
130. Zappasodi F, Salustri C, Babiloni C, et al. An observational study on the influence of the APOE-e4 allele on the correlation between 'free' copper toxicosis and EEG activity in Alzheimer disease. Brain Res 2008;1215:183-189
131. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14(1):55-61
132. Moir RD, Atwood CS, Huang X, et al. Mounting evidence for the involvement of zinc and copper in Alzheimer's disease. Eur J Clin Invest 1999;29:569-570
133. Gauthier E, Fortier I, Courchesne F, et al. Aluminum forms in drinking water and risk of Alzheimer's disease. Environ Res 2000;84:234-246
134. Neri LC, Hewitt D. Aluminium, Alzheimer's disease, and drinking water. Lancet 1991;338:390
135. Rondeau V, Jacqmin-Gadda H, Commenges D, et al. Aluminum and silica in drinking water and the risk of Alzheimer's disease or cognitive decline: findings from 15-year follow-up of the PAQUID cohort. Am J Epidemiol 2009;169:489-496
136. Polizzi S, Pira E, Ferrara M, et al. Neurotoxic effects of aluminium among foundry workers and Alzheimer's disease. Neurotoxicology 2002;23:761-774
137. Yumoto S, Kakimi S, Ohsaki A, Ishikawa A. Demonstration of aluminum in amyloid fibers in the cores of senile plaques in the brains of patients with Alzheimer's disease. J Inorg Biochem 2009;103:1579-1584
138. Hegde ML, Anitha S, Latha KS, et al. First evidence for helical transitions in supercoiled DNA by amyloid beta peptide (1-42) and aluminum: a new insight in understanding Alzheimer's disease. J Mol Neurosci 2004;22:19-31
139. Atamna H, Killilea DW, Killilea AN, Ames BN. Heme deficiency may be a factor in the mitochondrial and neuronal decay of aging. Proc Natl Acad Sci USA 2002;99:14807-14812
140. Rodella LF, Ricci F, Borsani E, et al. Aluminium exposure induces Alzheimer's disease-like histopathological alterations in mouse brain. Histol Histopathol 2008;23:433-439
141. Pratico D, Uryu K, Sung S, et al. Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J 2002;16:1138-1140
142. Ribes D, Colomina MT, Vicens P, Domingo JL. Effects of oral aluminum exposure on behavior and neurogenesis in a transgenic mouse model of Alzheimer's disease. Exp Neurol 2008;214:293-300
143. Drago D, Cavaliere A, Mascetra N, et al. Aluminum modulates effects of betaamyloid1-42 on neuronal calcium homeostasis and mitochondria functioning and is altered in a triple transgenic mouse model of Alzheimer's disease. Rejuvenation Res 2008;11:861-871
144. Korchazhkina OV, Ashcroft AE, Kiss T, Exley C. The degradation of Abeta (25-35) by the serine protease plasmin is inhibited by aluminium. J Alzheimers Dis 2002;4:357-367
145. Walton JR. Aluminum in hippocampal neurons from humans with Alzheimer's disease. Neurotoxicology 2006;27:385-394
146. Perl DP, Brody AR. Alzheimer's disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science 1980;208:297-299
147. Candy JM, McArthur FK, Oakley AE, et al. Aluminium accumulation in relation to senile plaque and neurofibrillary tangle formation in the brains of patients with renal failure. J Neurol Sci 1992;107:210-218
148. Bondy SC, Truong A. Potentiation of beta-folding of beta-amyloid peptide 25-35 by aluminum salts. Neurosci Lett 1999;267:25-28
149. Fasman GD, Moore CD. The solubilization of model Alzheimer tangles: reversing the beta-sheet conformation induced by aluminum with silicates. Proc Natl Acad Sci USA 1994;91:11232-11235
150. House E, Collingwood J, Khan A, et al. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J Alzheimers Dis 2004;6:291-301
151. Di Vaira M, Bazzicalupi C, Orioli P, et al. Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper (II) complexes. Inorg Chem 2004;43:3795-3797
152. Raman B, Ban T, Yamaguchi K, et al. Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid beta peptide. J Biol Chem 2005;280:16157-16162
153. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177
154. Treiber C, Simons A, Strauss M, et al. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. J Biol Chem 2004;279:51958-51964
155. Huang X, Atwood CS, Moir RD, et al. Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. J Biol Chem 1997;272:26464-26470
156. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-676
157. Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 2002;23:1031-1038
158. Wang Y, Branicky R, Stepanyan Z, et al. The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1. J Biol Chem 2009;284:314-323
159. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 2003;26:207-214
160. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot Phase 2 clinical trial. Arch Neurol 2003;60:1685-1691
161. Rodriguez-Rodriguez C, Sanchez de Groot N, Rimola A, et al. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease. J Am Chem Soc 2009;131:1436-1451
162. Sampson E, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2008;(1):CD005380
163. Adlard PA, Cherny RA, Finkelstein DI, et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008;59:43-55
164. Faux NG, Ritchie CW, Gunn A, et al. PBT2 rapidly improves cognition in Alzheimer's disease: additional Phase II analyses. J Alzheimers Dis 2010;20:509-516
165. Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008;7:779-786
166. Lee JY, Friedman JE, Angel I, et al. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 2004;25:1315-1321
167. Ji HF, Zhang HY. A new strategy to combat Alzheimer's disease. Combining radical-scavenging potential with metal-protein-attenuating ability in one molecule. Bioorg Med Chem Lett 2005;15:21-24
168. Avramovich-Tirosh Y, Amit T, Bar-Am O, et al. Physiological and pathological aspects of Abeta in iron homeostasis via 5¢UTR in the APP mRNA and the therapeutic use of iron-chelators. BMC Neurosci 2008;9(Suppl 2):S2
169. Yassin MS, Ekblom J, Xilinas M, et al. Changes in uptake of vitamin B12 and trace metals in brains of mice treated with clioquinol. J Neurol Sci 2000;173:40-44
170. Finefrock AE, Bush AI, Doraiswamy PM. Current status of metals as therapeutic targets in Alzheimer's disease. J Am Geriatr Soc 2003;51:1143-1148
171. Crapper McLachlan DR, Dalton AJ, Kruck TP, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991;337:1304-1308
172. Cuajungco MP, Faget KY, Huang X, et al. Metal chelation as a potential therapy for Alzheimer's disease. Ann NY Acad Sci 2000;920:292-304
173. Domingo JL. Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents. J Alzheimers Dis 2006;10:331-341
174. Avramovich-Tirosh Y, Amit T, Bar-Am O, et al. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhbitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem 2006;100:490-502
175. Avramovich-Tirosh Y, Bar-Am O, Amit T, et al. Up-regulation of hypoxia-inducible factor (HIF) -1beta and HIF-target genes in cortical neurons by the Novel Multifunctional Iron Chelator Anti-Alzheimer Drug, M30. Curr Alzheimer Res 2010;7:300-306
176. Youdim MB, Bar Am O, Yogev-Falach M, et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 2005;79:172-179
177. Dedeoglu A, Cormier K, Payton S, et al. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol 2004;39:1641-1649
178. Storr T, Scott LE, Bowen ML, et al. Glycosylated tetrahydrosalens as multifunctional molecules for Alzheimer's therapy. Dalton Trans 2009;28:3034-3043
179. Storr T, Merkel M, Song-Zhao GX, et al. Synthesis, characterization, and metal coordinating ability of multifunctional carbohydrate-containing compounds for Alzheimer's therapy. J Am Chem Soc 2007;129:7453-7463
180. Green DE, Bowen ML, Scott LE, et al. In vitro studies of 3-hydroxy-4- pyridinones and their glycosylated derivatives as potential agents for Alzheimer's disease. Dalton Trans 2010;39:1604-1615
181. Schugar H, Green DE, Bowen ML, et al. Combating Alzheimer's disease with multifunctional molecules designed for metal passivation. Angew Chem Int Ed Engl 2007;46:1716-1718
182. Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008;51:347-372
183. Wu WH, Lei P, Liu Q, et al. Sequestration of copper from beta-amyloid promotes selective lysis by cyclen-hybrid cleavage agents. J Biol Chem 2008;283:31657-31664
184. Sattin A, Muhoberac BB, Aprison MH, Schauf CL. Tetrahydroaminoacridine (THA) as a pharmacological probe in Alzheimer's disease (AD) and other neurodegenerative disorders. Med Hypotheses 1989;29:155-159
185. Shin RW, Kruck TP, Murayama H, Kitamoto T. A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer's disease. Brain Res 2003;96:139-146
186. Flora SJS, Mehta A, Satsangi K, et al. Aluminum-induced oxidative stress in rat brain: response to combined administration of citric acid and HEDTA. Comparative Biochemistry and Physiology Part C: Toxicol Pharmacol 2003;134:319-328
187. Liu G, Men P, Kudo W, et al. Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett 2009;455:187-190
188. Liu G, Men P, Harris PL, et al. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 2006;406:189-193
189. Liu G, Garrett MR, Men P, et al. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta 2005;1741:246-252
190. Liu G, Men P, Perry G, Smith MA. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol Biol 2010;610:123-144
191. Donnelly PS, Caragounis A, Du T, et al. Selective intracellular release of copper and zinc ions from bis (thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide. J Biol Chem 2008;283:4568-4577
192. Sigel H, Prijs B, McCormick DB, Shih JC. Stability and structure of binary and ternary complexes of alpha-lipoate and lipoate derivatives with Mn2+, Cu2+, and Zn2+ in solution. Arch Biochem Biophys 1978;187:208-214
193. Ou P, Tritschler HJ, Wolff SP. Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant? Biochem Pharmacol 1995;50:123-126
194. Lovell MA, Xie C, Xiong S, Markesbery WR. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J Alzheimers Dis 2003;5:229-239
195. Salinthone S, Yadav V, Bourdette DN, Carr DW. Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS. Endocr Metab Immune Disord Drug Targets 2008;8:132-142
196. Quinn JF, Bussiere JR, Hammond RS, et al. Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging 2007;28:213-225
197. Rossi L, Mazzitelli S, Arciello M, et al. Benefits from dietary polyphenols for brain aging and Alzheimer's disease. Neurochem Res 2008;33:2390-2400
198. Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21:8370-8377
199. Smith DG, Cappai R, Barnham KJ. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta 2007;1768:1976-1990
200. Mandel SA, Amit T, Weinreb O, et al. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci Ther 2008;14:352-365
201. Rezai-Zadeh K, Arendash GW, Hou H, et al. Green tea epigallocatechin-3- gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 2008;1214:177-187
202. Obregon DF, Rezai-Zadeh K, Bai Y, et al. ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallateinduced alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 2006;281:16419-16427
203. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002;156:445-453
204. Orgogozo JM, Dartigues JF, Lafont S, et al. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 1997;153:185-192
205. Truelsen T, Thudium D, Gronbaek M. Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology 2002;59:1313-1319
206. Vingtdeux V, Giliberto L, Zhao H, et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 2010;285:9100-9113
207. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004;61:82-88
208. Yoon I, Lee KH, Cho J. Gossypin protects primary cultured rat cortical cells from oxidative stress- and beta-amyloid-induced toxicity. Arch Pharm Res 2004;27:454-459 (Pubitemid 43073744)
209. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998;55:1409-1415
210. Maharaj DS, Maharaj H, Daya S, Glass BD. Melatonin and 6-hydroxymelatonin protect against iron-induced neurotoxicity. J Neurochem 2006;96:78-81
211. Squitti R, Lupoi D, Pasqualetti P, et al. Elevation of serum copper levels in Alzheimer's disease. Neurology 2002;59:1153-1161
212. Squitti R, Rossini PM, Cassetta E, et al. D-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest 2002;32:51-59
213. Hill GM, Brewer GJ, Juni JE, et al. Treatment of Wilson's disease with zinc. II. Validation of oral 64copper with copper balance. Am J Med Sci 1986;292:344-349
214. Brewer GJ. Copper toxicity in the general population. Clin Neurophysiol 2010;121:459-460
215. Squitti R, Zito G. Anti-copper therapies in Alzheimer's disease: new concepts. Recent Pat CNS Drug Discov 2009;4:209-219
216. Amit T, Avramovich-Tirosh Y, Youdim MB, Mandel S. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J 2008;22:1296-1305
217. Morse LJ, Payton SM, Cuny GD, Rogers JT. FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. J Mol Neurosci 2004;24:129-136
218. Brewer GJ. The use of copper-lowering therapy with tetrathiomolybdate in medicine. Expert Opin Investig Drugs 2009;18:89-97
219. Greig NH, Ruckle J, Comer P, et al. Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. Curr Alzheimer Res 2005;2:483-492
220. Bandyopadhyay S, Ni J, Ruggiero A, et al. A high-throughput drug screen targeted to the 5¢untranslated region of Alzheimer amyloid precursor protein mRNA. J Biomol Screen 2006;11:469-480
221. Chishti MA, Yang DS, Janus C, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001;276:21562-21570
222. Bodovitz S, Falduto MT, Frail DE, Klein WL. Iron levels modulate alpha-secretase cleavage of amyloid precursor protein. J Neurochem 1995;64:307-315
223. Bandyopadhyay S, Goldstein LE, Lahiri DK, Rogers JT. Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease. Curr Med Chem 2007;14:2848-2864
224. Bandyopadhyay S, Hartley DM, Cahill CM, et al. Interleukin-1alpha stimulates non-amyloidogenic pathway by alpha-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase. J Neurosci Res 2006;84:106-118
225. Qin W, Ho L, Wang J, et al. S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PLoS One 2009;4(1):e4183
226. Cho HH, Cahill CM, Vanderburg CR, et al. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem 2010: published online 29 Jun 2010, doi:10.1074/jbc. M110.149161
227. Beaudoin ME, Poirel VJ, Krushel LA. Regulating amyloid precursor protein synthesis through an internal ribosomal entry site. Nucleic Acids Res 2008;36:6835-6847
228. Wagner U, Utton M, Gallo JM, Miller CC. Cellular phosphorylation of tau by GSK-3beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 1996;109:1537-1543